Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac IPO & Placement Research, China biotech

Sekisui House REIT Placement - Accretive Deal and Extended Trading Helps

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

Sekisui House Reit / Equity Capital Markets

<p><a href="https://www.smartkarma.com/entities/7497" target="_blank" data-smartkarma-citation="entities:7497:1">Sekisui House Reit (3309 JP)</a> is raising USD 340 million to fund its acquisition of seven properties. In this insight, we will look at the company's current portfolio, the impact of the acquisition and capital raising. The reit is acquiring assets from sponsor at decent discount to the appraised value. Besides, the deal is DPU accretive. </p>

Sekisui House Reit (3309 JP) is raising USD 340 million to fund its acquisition of seven properties. In this insight, we will look at the company's current portfolio, the impact of the acquisition and capital raising. The reit is acquiring assets from sponsor at decent discount to the appraised value. Besides, the deal is DPU accretive. 

Sekisui House Reit Placement: Acquisition at Discount & DPU Accretive